Company intelligence / Profile preview

Latorius

Philadelphia, Pennsylvania, United Statescdn.clinicaltrials.gov ↗

Ownership: Private
Development stage: Other

Overview

Latus has demonstrated in preclinical non-human primate studies that its proprietary AAV-based gene therapies achieve high expression in targeted CNS regions with minimal off-tissue activity. The approach enables low-dose administration, aiming to improve safety and manufacturability. Clinical trials are expected to begin with the CLN2 program in late 2025.

Therapeutic areas: Neurology
Modalities: Gene therapyAdeno-associated virus (AAV)-based gene therapy
Industry: Biotech

Partnerships

No major pharma partnerships disclosed as of June 2025.

Beyond the preview

Go deeper on Latorius.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Latorius.

Explore the full profile